Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

PTC Therapeutics stock price, quote, forecast and news

PTCT
US69366J2006
A1W0MW

Price

31.54
Today +/-
-0.05
Today %
-0.19 %
P

PTC Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the PTC Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the PTC Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the PTC Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze PTC Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

PTC Therapeutics Stock Price History

DatePTC Therapeutics Price
9/6/202431.54 undefined
9/5/202431.60 undefined
9/4/202433.59 undefined
9/3/202433.41 undefined
8/30/202435.32 undefined
8/29/202435.53 undefined
8/28/202435.19 undefined
8/27/202435.32 undefined
8/26/202434.91 undefined
8/23/202434.15 undefined
8/22/202433.43 undefined
8/21/202433.93 undefined
8/20/202434.39 undefined
8/19/202434.46 undefined
8/16/202433.42 undefined
8/15/202433.04 undefined
8/14/202431.77 undefined
8/13/202431.87 undefined
8/12/202431.31 undefined

PTC Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into PTC Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by PTC Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects PTC Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of PTC Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into PTC Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing PTC Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on PTC Therapeutics’s growth potential.

PTC Therapeutics Revenue, EBIT and net profit per share

DatePTC Therapeutics RevenuePTC Therapeutics EBITPTC Therapeutics Net Income
2029e1.64 B undefined0 undefined378.17 M undefined
2028e1.32 B undefined314.33 M undefined171.82 M undefined
2027e1.07 B undefined104.51 M undefined-85.52 M undefined
2026e829.72 M undefined-14.58 M undefined-154.74 M undefined
2025e696.52 M undefined-179.55 M undefined-305.86 M undefined
2024e751.73 M undefined-242.88 M undefined-397.67 M undefined
2023937.82 M undefined-221.7 M undefined-626.6 M undefined
2022698.8 M undefined-414 M undefined-559 M undefined
2021538.6 M undefined-374.4 M undefined-523.9 M undefined
2020380.8 M undefined-421.2 M undefined-438.2 M undefined
2019307 M undefined-241.2 M undefined-251.6 M undefined
2018264.7 M undefined-115.7 M undefined-128.1 M undefined
2017194.4 M undefined-64.3 M undefined-79 M undefined
201682.7 M undefined-132.1 M undefined-142.1 M undefined
201536.8 M undefined-167.1 M undefined-170.4 M undefined
201425.2 M undefined-99.4 M undefined-93.8 M undefined
201334.7 M undefined-45.4 M undefined-66.4 M undefined
201233.9 M undefined-26.8 M undefined700,000 undefined
2011105.4 M undefined30.6 M undefined0 undefined
20055 M undefined-24.1 M undefined-22.9 M undefined
20041.6 M undefined-24.5 M undefined-23.6 M undefined
2003800,000 undefined-21.6 M undefined-21.4 M undefined
2002200,000 undefined-14.2 M undefined-13.5 M undefined
20010 undefined-9.2 M undefined-8.2 M undefined

PTC Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2001200220032004200520112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000.010.110.030.030.030.040.080.190.260.310.380.540.70.940.750.70.831.071.321.64
----400.002,000.00-68.573.03-26.4744.00127.78136.5936.0816.2923.7841.5829.7434.24-19.85-7.3219.1128.5923.3625.02
-----------97.4295.4595.7795.0094.0593.7093.06------
00000000000189252294361506654872000000
-9-14-21-24-2430-26-45-99-167-132-64-115-241-421-374-414-221-242-179-141043140
----2,400.00-480.0028.57-78.79-132.35-396.00-463.89-160.98-32.99-43.56-78.50-110.79-69.52-59.31-23.59-32.22-25.72-1.699.7623.88-
-8-13-21-23-2200-66-93-170-142-79-128-251-438-523-559-626-397-305-154-85171378
-62.5061.549.52-4.35---40.9182.80-16.47-44.3762.0396.0974.5019.416.8811.99-36.58-23.17-49.51-44.81-301.18121.05
10.810.810.810.810.823.723.712.831.633.63439.246.658.96670.571.774.84000000
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The PTC Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the PTC Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
200420052011201220132014201520162017201820192020202120222023
                             
0.030.040.0300.140.320.340.230.190.230.691.10.770.410.88
001.2114.411.124.940.467.955.569.9110.5155.6160.82
000000000000000
0000000010.816.119.318.715.921.830.58
0.71.13.40.91.63.95.94.76.79.217.939.554.7105.7150.49
0.030.040.0300.150.320.360.260.250.320.781.230.950.691.22
5.24.710.88.36.79.297.48.412.735.2118.2130175178.99
1003000000000000000
000000000000000
00000000133701710.5715.3724.8705.9379.5
00000000082.382.382.382.382.382.34
000.30.20.10.50.40.61.22.316.460.646.548.636.25
0.010.010.010.010.010.010.010.010.140.80.840.980.981.010.68
0.040.040.040.010.150.330.370.270.391.121.622.211.941.711.9
                             
103.6130.1214.480.8000000.10.10.10.10.10.08
000.010.180.470.720.820.860.971.291.82.172.122.312.47
-69.3-92.2-250.6-277.2-328.8-422.6-593-735.1-814.1-938.9-1,190.5-1,628.9-2,098-2,657-3,283.58
00000.1-0.4-0.6-1.33.91.4-11.3-62.9-23.75.3-1.61
00000-0.4-0.6-0.2000.81.9-0.6-0.50.33
34.738.4-24.2-18.8136.5298.3226119.5156.3350.7594.5481.91.4-347.1-818.56
1.71.29.63.97.119.832.635.158.8100.651.57384.791.183.22
1.52.73.53.15.19.312.613.617.727.67092105.6126.1116.32
00.32316.70.93.40.10.95.626.994.490.1107.2114206.25
000000000000000
0.90.57.14.40000011.72022.3211.875.1197.31
4.14.743.228.113.132.545.349.682.1166.8235.9277.4509.3406.3603.1
0000000.090.10.150.140.290.990.981.281.92
000000000122130.9136.7137.1102.855.91
00.120.73.32.22.321.98.2338.3368.9321.3313.5267.5134.07
000.030000.090.10.150.60.791.451.431.652.11
00.010.070.030.020.030.140.150.240.771.031.731.942.052.71
0.040.040.040.010.150.330.370.270.391.121.622.211.941.711.9
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of PTC Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand PTC Therapeutics's financial health and stability.

Assets

PTC Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that PTC Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of PTC Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into PTC Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2003200420052011201220132014201520162017201820192020202120222023
-21-23-2230-26-51-93-170-142-79-128-251-438-523-559-626
1112222231726324364128236
00000000000850-34-46
200-57-25-12134-813142036-23-9426
10053234072796893133228335313383
000210004677991836
000000000112267414
-16-22-20-20-47-46-57-124-103-10-27-98-194-251-356-158
0-10000-4-2-1-3-7-13-17-28-32-28
13-20-1270-127-145-2010413-42-387-561219290-176
14-190270-126-140-1810616-35-373-543247322-148
0000000000000000
-1-10-7-6-501500400267-46-2148-301
341426029192237804131345103237129
321326-72218723715404413161366820167646
0000000-400006110-51917
0000000000000000
29-2940-251234805357126-79-1998314
-16.9-23.53-21.68-20.94-48.12-47.77-61.93-127.06-105.35-13.16-34.74-112.4-211.91-279.54-388.67-186.86
0000000000000000

PTC Therapeutics stock margins

The PTC Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PTC Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PTC Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the PTC Therapeutics's sales revenue. A higher gross margin percentage indicates that the PTC Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the PTC Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the PTC Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the PTC Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the PTC Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the PTC Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

PTC Therapeutics Margin History

PTC Therapeutics Gross marginPTC Therapeutics Profit marginPTC Therapeutics EBIT marginPTC Therapeutics Profit margin
2029e93.02 %0 %22.99 %
2028e93.02 %23.9 %13.07 %
2027e93.02 %9.8 %-8.02 %
2026e93.02 %-1.76 %-18.65 %
2025e93.02 %-25.78 %-43.91 %
2024e93.02 %-32.31 %-52.9 %
202393.02 %-23.64 %-66.81 %
202293.6 %-59.24 %-79.99 %
202194 %-69.51 %-97.27 %
202095.01 %-110.61 %-115.07 %
201996.03 %-78.57 %-81.95 %
201895.24 %-43.71 %-48.39 %
201797.63 %-33.08 %-40.64 %
201693.02 %-159.73 %-171.83 %
201593.02 %-454.08 %-463.04 %
201493.02 %-394.44 %-372.22 %
201393.02 %-130.84 %-191.35 %
201293.02 %-79.06 %2.06 %
201193.02 %29.03 %0 %
200593.02 %-482 %-458 %
200493.02 %-1,531.25 %-1,475 %
200393.02 %-2,700 %-2,675 %
200293.02 %-7,100 %-6,750 %
200193.02 %0 %0 %

PTC Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The PTC Therapeutics earnings per share therefore indicates how much revenue PTC Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue PTC Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates PTC Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of PTC Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating PTC Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

PTC Therapeutics Revenue, EBIT and net profit per share

DatePTC Therapeutics Sales per SharePTC Therapeutics EBIT per sharePTC Therapeutics Earnings per Share
2029e21.39 undefined0 undefined4.92 undefined
2028e17.1 undefined0 undefined2.23 undefined
2027e13.86 undefined0 undefined-1.11 undefined
2026e10.79 undefined0 undefined-2.01 undefined
2025e9.06 undefined0 undefined-3.98 undefined
2024e9.77 undefined0 undefined-5.17 undefined
202312.53 undefined-2.96 undefined-8.37 undefined
20229.75 undefined-5.77 undefined-7.8 undefined
20217.64 undefined-5.31 undefined-7.43 undefined
20205.77 undefined-6.38 undefined-6.64 undefined
20195.21 undefined-4.1 undefined-4.27 undefined
20185.68 undefined-2.48 undefined-2.75 undefined
20174.96 undefined-1.64 undefined-2.02 undefined
20162.43 undefined-3.89 undefined-4.18 undefined
20151.1 undefined-4.97 undefined-5.07 undefined
20140.8 undefined-3.15 undefined-2.97 undefined
20132.71 undefined-3.55 undefined-5.19 undefined
20121.43 undefined-1.13 undefined0.03 undefined
20114.45 undefined1.29 undefined0 undefined
20050.46 undefined-2.23 undefined-2.12 undefined
20040.15 undefined-2.27 undefined-2.19 undefined
20030.07 undefined-2 undefined-1.98 undefined
20020.02 undefined-1.31 undefined-1.25 undefined
20010 undefined-0.85 undefined-0.76 undefined

PTC Therapeutics business model

PTC Therapeutics Inc. is a biopharmaceutical company based in South Plainfield, New Jersey. The company was founded in 1998 and focuses on the research and development of drugs for the treatment of rare diseases. The company has two main divisions: product research and development, and science and innovation. Its product range includes several drugs for the treatment of rare diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and cystic fibrosis. One of its key products is Translarna, the first RNA-targeted drug approved for the treatment of Duchenne muscular dystrophy. Another product is Evrysdi, approved for the treatment of spinal muscular atrophy. PTC Therapeutics also has a pipeline of drugs being tested in clinical trials for various rare diseases. The company is committed to promoting innovation and has partnerships with academic institutions and other companies to explore and develop new therapies. Overall, PTC Therapeutics aims to improve the lives of patients with rare diseases through innovative treatments. PTC Therapeutics is one of the most popular companies on Eulerpool.com.

PTC Therapeutics SWOT Analysis

Strengths

PTC Therapeutics Inc possesses several strengths that contribute to its competitive position and growth potential. These strengths include:

  • Strong Research and Development Capabilities: PTC Therapeutics Inc has a robust R&D division, allowing it to innovate and develop new drugs and therapies.
  • Patented Technologies: The company owns several patented technologies, providing it with a competitive advantage and potential revenue streams.
  • Strategic Partnerships: PTC Therapeutics Inc has established partnerships with leading pharmaceutical companies, enhancing its market reach and access to resources.
  • Diverse Product Pipeline: The company has a diverse portfolio of products in various stages of development, reducing dependency on a single drug.

Weaknesses

Despite its strengths, PTC Therapeutics Inc faces certain weaknesses that may impact its performance and market position. These weaknesses include:

  • Dependency on a Few Key Products: The success of PTC Therapeutics Inc heavily relies on a few key products, making it vulnerable to market uncertainties or failures in development.
  • Limited Market Presence: Compared to some of its competitors, the company has a relatively smaller market presence, constraining its market reach and visibility.
  • Regulatory Challenges: The pharmaceutical industry is subject to stringent regulatory requirements, and any regulatory hurdles can delay product approvals and impact the company's timelines.

Opportunities

PTC Therapeutics Inc can leverage various opportunities to expand its market share and drive growth. These opportunities include:

  • Emerging Markets: The company can explore untapped emerging markets, expanding its customer base and revenue streams.
  • Advancements in Genetic Therapies: With increasing advancements in genetic therapies, PTC Therapeutics Inc can capitalize on this growing market and develop targeted treatments.
  • Strategic Acquisitions: The company can consider strategic acquisitions to augment its product pipeline, enhance research capabilities, and gain access to new markets.

Threats

PTC Therapeutics Inc is exposed to several threats that may hinder its growth and competitiveness. These threats include:

  • Intense Competition: The pharmaceutical industry is highly competitive, with numerous companies vying for market share, which may impact pricing and market penetration.
  • Pricing Pressures: Healthcare cost containment measures and pricing pressures can affect the profitability of PTC Therapeutics Inc's products.
  • Intellectual Property Challenges: The company may face patent disputes or challenges from competitors, jeopardizing its exclusive rights to key technologies.

PTC Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

PTC Therapeutics historical P/E ratio, EBIT, and P/S ratio.

PTC Therapeutics shares outstanding

The number of shares was PTC Therapeutics in 2023 — This indicates how many shares 74.838 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue PTC Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates PTC Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of PTC Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating PTC Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for PTC Therapeutics.

PTC Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.07 -1.27  (-18.68 %)2024 Q2
3/31/2024-1.27 -1.2  (5.18 %)2024 Q1
12/31/20230.51 -0.24  (-147.48 %)2023 Q4
9/30/2023-1.19 -1.76  (-47.42 %)2023 Q3
6/30/2023-1.27 -2.66  (-109.51 %)2023 Q2
3/31/2023-1.32 -1.88  (-41.94 %)2023 Q1
12/31/2022-1.62 -1.89  (-16.38 %)2022 Q4
9/30/2022-1.27 -1.53  (-20.75 %)2022 Q3
6/30/2022-1.36 -2.13  (-56.73 %)2022 Q2
3/31/2022-1.54 -1.78  (-15.82 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the PTC Therapeutics stock

Eulerpool World ESG Rating (EESG©)

72/ 100

🌱 Environment

55

👫 Social

99

🏛️ Governance

64

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees50.2
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

PTC Therapeutics list of shareholders

%
Name
Stocks
Change
Date
9.65155 % RTW Investments L.P.7,423,970188,77412/31/2023
8.92356 % Armistice Capital LLC6,864,000714,00012/31/2023
7.46668 % BlackRock Institutional Trust Company, N.A.5,743,370524,77312/31/2023
6.02438 % State Street Global Advisors (US)4,633,9551,465,09512/31/2023
5.20021 % Camber Capital Management LP4,000,000012/31/2023
4.84351 % Cowen & Co., LLC3,725,6262,926,11512/31/2023
3.39651 % Janus Henderson Investors2,612,593-459,72712/31/2023
2.09468 % Geode Capital Management, L.L.C.1,611,22589,39612/31/2023
12.76209 % Wellington Management Company, LLP9,816,603380,41512/31/2023
11.42467 % The Vanguard Group, Inc.8,787,854855,35412/31/2023
1
2
3
4
5
...
10

PTC Therapeutics Executives and Management Board

Dr. Matthew Klein51
PTC Therapeutics President, Chief Executive Officer, Director (since 2020)
Compensation 5.01 M
Mr. Mark Boulding62
PTC Therapeutics Executive Vice President, Chief Legal Officer
Compensation 4.29 M
Mr. Eric Pauwels62
PTC Therapeutics Chief Business Officer
Compensation 2.99 M
Dr. Neil Almstead56
PTC Therapeutics Chief Technical Operations Officer
Compensation 2.67 M
Ms. Christine Utter45
PTC Therapeutics Senior Vice President, Chief Accounting Officer, Head - People Services
Compensation 1.7 M
1
2
3
4

Most common questions regarding PTC Therapeutics

What values and corporate philosophy does PTC Therapeutics represent?

PTC Therapeutics Inc represents core values of innovation, dedication, and patient-centricity. With a strong corporate philosophy, the company is committed to developing transformative therapies for patients with rare diseases caused by genetic mutations. PTC Therapeutics Inc focuses on leveraging cutting-edge science and technology to develop targeted treatments, addressing unmet medical needs. By fostering collaboration and embracing a patient-first approach, PTC Therapeutics Inc strives to improve the quality of life for individuals and families affected by these rare and debilitating conditions. Through their relentless pursuit of scientific advancements, PTC Therapeutics Inc demonstrates their commitment to making a meaningful difference in the lives of patients worldwide.

In which countries and regions is PTC Therapeutics primarily present?

PTC Therapeutics Inc is primarily present in various countries and regions across the globe. As a pharmaceutical company, PTC Therapeutics Inc operates in multiple markets to ensure patient access to its innovative therapies. The company's presence extends to regions such as North America, including the United States and Canada, as well as Europe, with a focus on countries like Germany, France, and Italy. PTC Therapeutics Inc continues to expand its presence in other international markets, driven by its commitment to improving the lives of patients worldwide.

What significant milestones has the company PTC Therapeutics achieved?

PTC Therapeutics Inc has achieved several significant milestones. One notable accomplishment includes the approval of their drug, Translarna™ (ataluren), by the European Medicines Agency (EMA). This groundbreaking treatment is designed to address the underlying cause of nonsense mutation Duchenne muscular dystrophy (nmDMD). Additionally, PTC Therapeutics Inc has successfully expanded its global footprint by establishing commercialization agreements for Translarna™ in various countries. These achievements highlight PTC Therapeutics Inc's commitment to advancing innovative therapies and improving the lives of patients with genetic disorders like nmDMD.

What is the history and background of the company PTC Therapeutics?

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of orally administered small molecule drugs. Founded in 1998, PTC Therapeutics initially focused on RNA biology and identified a new class of RNA-modulating small molecules. Since its inception, the company has been committed to addressing the unmet medical needs of patients with rare and genetic disorders. Today, PTC Therapeutics is a global leader in the development of treatments for rare diseases, with a portfolio that includes multiple therapies targeting various genetic mutations. Through its innovative approach, PTC Therapeutics aims to improve the lives of patients worldwide.

Who are the main competitors of PTC Therapeutics in the market?

The main competitors of PTC Therapeutics Inc in the market are companies like Sarepta Therapeutics, Vertex Pharmaceuticals, and BioMarin Pharmaceutical.

In which industries is PTC Therapeutics primarily active?

PTC Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of PTC Therapeutics?

PTC Therapeutics Inc.'s business model revolves around researching, developing, and commercializing innovative therapies for rare genetic disorders. The company focuses on utilizing its expertise in RNA biology and small molecule pharmacology to develop treatments that address the underlying cause of diseases. PTC Therapeutics Inc. aims to increase the production of functional proteins in patients with genetic disorders by targeting RNA splicing or protein translational regulation. Through strategic partnerships, clinical trials, and regulatory approvals, PTC Therapeutics Inc. strives to bring transformative treatments to patients with limited therapeutic options, ultimately improving their quality of life.

What is the P/E ratio of PTC Therapeutics 2024?

The PTC Therapeutics P/E ratio is -5.94.

What is the P/S ratio of PTC Therapeutics 2024?

The PTC Therapeutics P/S ratio is 3.14.

What is the AlleAktien quality score of PTC Therapeutics?

The AlleAktien quality score for PTC Therapeutics is 6/10.

What is the revenue of PTC Therapeutics 2024?

The expected PTC Therapeutics revenue is 751.73 M USD.

How high is the profit of PTC Therapeutics 2024?

The expected PTC Therapeutics profit is -397.67 M USD.

What is the business model of PTC Therapeutics

PTC Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapies for rare diseases. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey, USA. PTC Therapeutics Inc offers various products and solutions to treat diseases and conditions that are often neglected due to their rarity. These products are offered in three main areas: transcriptional regulation, DNA modification, and RNA technology. The products range from drugs to diagnostic tests to medical devices. In the transcriptional regulation division, PTC Therapeutics Inc is working on the development of small molecule drugs to regulate genes associated with various genetic diseases such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The most well-known product developed in this area is Translarna (Ataluren), which is approved for the treatment of Duchenne muscular dystrophy. The second area, DNA modification, focuses on developing therapies to correct targeted mutations in the genome. This includes the CRISPR/Cas9 system, which enables targeted genome editing. Along with RNA technology, which is the focus of the third area of the company, new possibilities for treating rare diseases are emerging. PTC Therapeutics Inc has already entered into various collaborations with biotech companies such as GenEdit, Censa Pharmaceuticals, and Beam Therapeutics. Another important core product of PTC Therapeutics Inc is the SMA360 diagnostic test, which aims to identify newly diagnosed infants and toddlers with spinal muscular atrophy (SMA). SMA360 is being developed in collaboration with Invitae and Biogen, and it enables fast and precise diagnosis of SMA. Due to its advanced pipeline and diversified product portfolio, PTC Therapeutics Inc has already achieved several milestones. In 2018, the company received approval for Emflaza in the US, a drug for the treatment of DMD. Further clinical trials are in the development phase. In terms of PTC Therapeutics Inc's business model, the development and commercialization of therapies for rare diseases are an important part. PTC Therapeutics Inc has a diversified product portfolio consisting of drugs, diagnostic tests, and medical devices. The company also collaborates with other companies in the biotech industry and partners with startups and universities in the research and development field. PTC Therapeutics Inc has experienced impressive growth in recent years and has the potential to develop and implement innovative therapies and solutions for rare diseases. The company has not only drawn interest in the industry but also from investors and is facing promising challenges in the future.

What is the PTC Therapeutics dividend?

PTC Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does PTC Therapeutics pay dividends?

The dividend cannot currently be calculated for PTC Therapeutics or the company does not pay out a dividend.

What is the PTC Therapeutics ISIN?

The ISIN of PTC Therapeutics is US69366J2006.

What is the PTC Therapeutics WKN?

The WKN of PTC Therapeutics is A1W0MW.

What is the PTC Therapeutics ticker?

The ticker of PTC Therapeutics is PTCT.

How much dividend does PTC Therapeutics pay?

Over the past 12 months, PTC Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PTC Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of PTC Therapeutics?

The current dividend yield of PTC Therapeutics is .

When does PTC Therapeutics pay dividends?

PTC Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PTC Therapeutics?

PTC Therapeutics paid dividends every year for the past 0 years.

What is the dividend of PTC Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is PTC Therapeutics located?

PTC Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von PTC Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PTC Therapeutics from 9/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did PTC Therapeutics pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of PTC Therapeutics in the year 2023?

In the year 2023, PTC Therapeutics distributed 0 USD as dividends.

In which currency does PTC Therapeutics pay out the dividend?

The dividends of PTC Therapeutics are distributed in USD.

All fundamentals about PTC Therapeutics

Our stock analysis for PTC Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PTC Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.